Brief: Formosa Pharmaceuticals Announces Licensing Agreement With Rxilient
03/12/2025 12:39
Dec 3 (Reuters) - Formosa Pharmaceuticals Inc 6838.TW: FORMOSA PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH RXILIENT, FOR COMMERCIALIZATION OF CLOBETASOL PROPIONATE OPHTHALMIC SUSPENSION FOR THE TREATMENT OF INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY Source text: ID:nPn7Dk75Ta Further company coverage: 6838.TW ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Formosa Pharmaceuticals
See all newsBrief: Formosa Pharmaceuticals Announces Licensing Agreement With Rxilient
Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
US FDA approves Eyenovia's eye drug, Formosa Pharma says (updated)
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%